Astec Lifesciences Limited (IN:ASTEC)
:ASTEC
Want to see IN:ASTEC full AI Analyst Report?
Top Page
Astec Lifesciences Limited
(ASTEC)
Select Model
Select Model
Rating:47Neutral
Price Target:
₹716.00
▲(1.78% Upside)
Action:ReiteratedDate:04/29/26
The score is primarily held down by weak financial performance (sustained losses and significant cash burn alongside higher leverage). Technicals are a partial offset with moderately positive momentum, but valuation is constrained by the negative P/E (loss-making) and lack of dividend yield data.
Positive Factors
Integrated product mix
Astec's vertically integrated portfolio—technical actives, chemical intermediates, and finished formulations—provides structural resilience. Owning multiple value‑chain stages supports margin capture, product substitution if one segment weakens, and cross‑sell opportunities to both domestic and export customers over the medium term.
Negative Factors
Sustained losses and cash burn
Large, persistent net losses and heavy cash burn materially weaken internal funding capacity and erode equity cushions. Over a multi‑month horizon this forces reliance on external financing or asset sales, constrains reinvestment, and raises the risk that operating plans must be cut if cash flows do not show durable improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated product mix
Astec's vertically integrated portfolio—technical actives, chemical intermediates, and finished formulations—provides structural resilience. Owning multiple value‑chain stages supports margin capture, product substitution if one segment weakens, and cross‑sell opportunities to both domestic and export customers over the medium term.
Read all positive factors
Astec Lifesciences Limited (ASTEC) vs. iShares MSCI India ETF (INDA)
Market Cap
₹15.54B
Dividend YieldN/A
Average Volume (3M)412.49K
Price to Earnings (P/E)―
Beta (1Y)1.49
Revenue Growth17.53%
EPS Growth43.42%
CountryIN
Employees606
SectorBasic Materials
Sector Strength58
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)0.50
Shares Outstanding22,282,238
10 Day Avg. Volume47,730
30 Day Avg. Volume412,490
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)2.96
Price to Sales (P/S)2.58
P/FCF Ratio-9.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)12.6
Revenue Forecast (FY)₹6.66B
Astec Lifesciences Limited Business Overview & Revenue Model
Company Description
Astec LifeSciences Limited, together with its subsidiaries, manufactures, distributes, and sells agrochemicals active ingredients and pharmaceutical intermediates in India. It manufactures a range of fungicides, insecticides, herbicides, and inter...
How the Company Makes Money
Astec Lifesciences makes money primarily by manufacturing and selling agrochemical products across three broad categories: (1) technical/active ingredients (the core pesticide/herbicide/fungicide molecules sold to formulators and agrochemical comp...
Astec Lifesciences Limited Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
42
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.78B | 4.48B | 3.81B | 4.58B | 6.28B | 6.77B |
| Gross Profit | 1.12B | 419.01M | -685.16M | 1.33B | 2.27B | 2.86B |
| EBITDA | -150.01M | -45.26M | -662.07M | -2.69M | 893.14M | 1.65B |
| Net Income | -1.14B | -809.17M | -1.35B | -469.30M | 255.65M | 898.59M |
Balance Sheet | ||||||
| Total Assets | 8.83B | 9.42B | 8.81B | 9.75B | 9.79B | 8.97B |
| Cash, Cash Equivalents and Short-Term Investments | 96.91M | 122.51M | 8.55M | 16.47M | 27.54M | 33.44M |
| Total Debt | 3.67B | 4.49B | 5.55B | 4.94B | 3.41B | 2.79B |
| Total Liabilities | 4.69B | 5.51B | 6.46B | 6.05B | 5.60B | 5.00B |
| Stockholders Equity | 4.14B | 3.91B | 2.35B | 3.69B | 4.19B | 3.96B |
Cash Flow | ||||||
| Free Cash Flow | -234.96M | -1.18B | -302.20M | -1.25B | -426.03M | -803.74M |
| Operating Cash Flow | -199.52M | -1.13B | -83.99M | 102.21M | 746.56M | 236.04M |
| Investing Cash Flow | -73.41M | -49.07M | -152.30M | -1.35B | -1.13B | -1.04B |
| Financing Cash Flow | 297.62M | 1.27B | 237.33M | 1.25B | 377.70M | 804.77M |
Astec Lifesciences Limited Technical Analysis
Positive
703.50
Price Trends
612.35
Positive
661.81
Positive
737.69
Negative
Market Momentum
21.31
Negative
65.48
Neutral
86.17
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ASTEC, the sentiment is Positive. The current price of 703.5 is above the 20-day moving average (MA) of 591.18, above the 50-day MA of 612.35, and below the 200-day MA of 737.69, indicating a neutral trend. The MACD of 21.31 indicates Negative momentum. The RSI at 65.48 is Neutral, neither overbought nor oversold. The STOCH value of 86.17 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ASTEC.
Astec Lifesciences Limited Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ₹13.20B | -28.19 | ― | 2.59% | -17.51% | -106.98% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
60 Neutral | ₹27.65B | 29.38 | ― | 0.97% | 8.37% | 19.15% | |
56 Neutral | ₹14.39B | 26.88 | ― | 0.24% | 14.39% | 75.07% | |
49 Neutral | ₹8.72B | -10.64 | ― | 0.39% | ― | ― | |
47 Neutral | ₹15.54B | -14.31 | ― | ― | 17.53% | 43.42% | |
46 Neutral | ₹7.30B | -247.22 | ― | 0.34% | -11.76% | 1526.28% |
* Basic Materials Sector Average
IN:ASTEC
Astec Lifesciences Limited
697.50
28.58
4.27%
IN:HERANBA
Heranba Industries Limited
217.85
-45.34
-17.23%
IN:IGPL
IG Petrochemicals Ltd.
428.75
9.13
2.18%
IN:IOLCP
IOL Chemicals & Pharmaceuticals Ltd.
94.20
30.07
46.89%
IN:PUNJABCHEM
Punjab Chemicals & Crop Protection Ltd.
1,173.60
100.79
9.39%
IN:UNIENTER
Uniphos Enterprises Limited
105.00
-55.77
-34.69%
Astec Lifesciences Limited Corporate Events
Astec LifeSciences Clears FY26 Results, Sets AGM and Board Reshuffle
Apr 27, 2026
Astec LifeSciences Limited’s board has approved the audited standalone and consolidated financial results for the quarter and full year ended 31 March 2026, with statutory auditors issuing unmodified opinions, underscoring the integrity of t...
Astec LifeSciences Clears FY26 Results, Sets AGM and Seeks Shareholder Nod on Board Changes
Apr 27, 2026
Astec LifeSciences Limited’s board has approved the audited standalone and consolidated financial results for the quarter and full year ended 31 March 2026, along with the cash flow statement and statement of assets and liabilities. The stat...
Exchange Seeks Clarification from Astec LifeSciences After Sharp Share Price Move
Apr 17, 2026
Astec LifeSciences Limited has experienced a significant movement in its share price, prompting the stock exchange to seek updated and relevant information from the company. The exchange’s action is aimed at safeguarding investor interests a...
Astec Lifesciences fully exits small solar SPV stake in Clean Max Andes
Mar 9, 2026
Astec Lifesciences Limited has exited its investment in Clean Max Andes Private Limited, a special purpose vehicle created with Clean Max Enviro Energy Solutions for group captive solar power generation, by selling its entire 26% equity stake. The...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.